全球局部抗菌牙周治療市場：市場規模、佔有率和趨勢分析（2026-2032 年）

全球局部抗菌牙周治療市場報告（至2032年）

2025年，全球局部抗菌牙周治療市場規模超過2.4億美元。預計未來將以-0.7%的年複合成長率萎縮，到2032年將略高於2.3億美元。

這份綜合報告涵蓋了全球局部抗菌牙周治療市場。該市場作為一個整體進行分析，未進行進一步細分。

該分析包括銷售量、平均售價（ASP）、市場規模、成長趨勢、市場促進因素和限制因素、截至2032年的市場預測以及截至2022年的歷史資料。還涵蓋了近期併購、公司簡介、產品系列和主要參與者。

患者對非手術牙周治療的偏好以及在刮治和牙根整平術中聯合使用局部抗菌療法是推動市場需求的主要因素。然而，市場飽和、保險償付問題以及人們對其他治療方法日益成長的興趣限制了市場成長。

市場概覽

全球局部抗菌牙周治療市場涵蓋了用於牙周疾病治療輔助性治療的各種產品。這些治療方法通常直接應用於牙周袋，以幫助抑制細菌活性，並改善齦下刮治和牙根整平術後的臨床效果。

由於該市場著重局部抗菌療法，而非涵蓋多種產品類型或器械類別，因此將其作為單一細分市場進行分析。此類產品主要用於牙周袋患者，局部治療有助於控制病情進展。

與牙周手術治療相比，局部抗菌牙周治療費用較低，創傷較少。因此，對於輕度至中度牙周疾病患者，當手術治療因費用、保險覆蓋範圍或治療意願等因素受到限制時，局部抗菌牙周治療尤為適用。

儘管牙周治療在臨床上發揮重要作用，但預計在預測期內市場規模將略有萎縮。產品滲透率趨於成熟、保險償付限制以及部分市場中其他牙周治療方法（包括雷射療法）的日益普及，都對市場需求構成了壓力。

市場促進因素

非手術牙周治療的偏好仍是局部抗菌牙周治療市場的主要動力。許多患者傾向於選擇無需手術、減輕不適感且恢復時間短的治療方法。局部抗菌治療產品易於獲取，通常與齦下刮治和牙根整平術聯合使用，作為常規牙周護理的一部分。

這些治療方法為輕度至中度牙周病患者提供了切實可行的選擇。將抗生素直接注射到牙周袋內，無需進行侵入性較大的手術即可有效控制局部病情。因此，當手術不適合、不必要或經濟條件不允許時，這些治療方法尤其適用。

保險償付的限制也促使人們繼續使用低成本的牙周治療方法。在許多市場，牙科保險對高級牙周治療的覆蓋範圍仍然有限。這導致患者不願接受昂貴的手術，維持了對局部抗菌療法的需求，將其視為牙周疾病管理中經濟有效的替代方案。

市場限制

保險償付不足仍然是牙周病和牙科治療市場的主要阻礙因素。當患者面臨高額自付費用時，他們可能會推遲或避免接受更高級的牙周治療。這會影響牙周治療的整體流程，並降低患者接受更全面治療的意願。

同時，局部抗菌藥物市場本身也面臨市場成熟和飽和所帶來的壓力。主要產品已上市多年，該領域大幅擴張的空間有限。在成熟市場中，需求往往更多地受到替代用途、臨床實踐和治療方案的驅動，而非新患者的接受度。

其他治療方法也帶來了壓力。在北美，牙周雷射治療的日益普及影響局部抗生素市場。雖然局部抗生素仍發揮重要作用，但來自其他治療方法的競爭降低其市場佔有率，這可能導致預測期內市場萎縮。

市場範圍和資料範圍

• 量化範圍：市場規模、市場佔有率、市場預測、市場成長率、銷售量、平均售價。
• 定性範圍：市場促進因素和限制因素、市場規模和成長趨勢、近期併購、公司簡介、產品系列和主要競爭對手。
• 目標時期：基準年為2025年，預測至2032年，歷史資料截至2022年。
• 資料類型包括：銷售量、平均售價、市場規模和成長趨勢、市場促進因素和限制因素、到2032年的市場預測、歷史資料、近期併購、公司簡介和產品系列。
• 方法注記：市場收入採用銷售量和平均售價計算。由於本報告局部抗菌牙周治療市場進行整體分析，因此重點關注整體市場表現、競爭格局、價格趨勢和治療方法模式。

本報告目的是幫助讀者評估非手術治療偏好、償付限制、市場飽和度和替代牙周治療如何影響全球局部抗菌牙周治療市場。

目標市場及區隔

局部抗菌牙周治療市場

局部抗菌牙周治療市場已作為一個整體進行分析，未進行進一步細分。

市場包括局部抗菌療法，最常與齦下刮治和牙根整平術結合使用，作為牙周治療的輔助性治療。

每個市場指標都透過相關的定量指標進行分析，例如市場規模、市場佔有率、市場預測、市場成長率、銷售量和平均售價。

競爭分析

OraPharma公司的ARESTIN®目前佔據全球牙周治療局部抗生素市場的大部分佔有率。 ARESTIN®是一種局部抗生素，可作為齦下刮治和牙根整平術的輔助用藥，含有1毫克米諾四環素米諾環素微球，目的是到達深牙周袋。

ARESTIN®於1996年上市，並於2001年獲得FDA核准。儘管該產品仍保持著市場主導地位，但其銷售額逐年下降，低於年度銷售預期。這種下降並非主要由於其他局部抗生素的市場佔有率成長所致，而是受到整體市場飽和以及牙周雷射治療日益普及（尤其是在北美地區）的影響。

PerioChip® 已成為全球第二大競爭對手，並在歐洲佔據領先地位。該產品透過經銷商銷往世界各地，在德國、英國、比荷盧經濟聯盟、奧地利和其他國家，Dexcel Pharma 透過其子公司和合作夥伴進行銷售。 PerioChip® 是一種小型可生物分解的明膠基質，含有 2.5 毫克葡萄糖酸氯己定。

到2025年，Ligosan成為全球第三名，歐洲第二大佔有率。 Ligosan®緩釋劑主要由Kulzer公司銷售，是一種以多西環素為基礎的凝膠，可釋放到牙周囊袋中。

科技和醫療治療的發展趨勢

在這個市場中，局部給藥仍然是核心治療模式。產品目的是將抗菌劑直接輸送到牙周袋內，支持局部治療，同時最大限度地減少侵入性手術的需求。

齦上潔治和牙根整平術的聯合應用仍然是主要的臨床治療流程。這些治療方法通常並非作為獨立的解決方案，而是作為更全面的牙周管理系統的一部分。

可生物分解配方仍然非常重要，因為它們可以簡化治療並減少取出的需要。例如，PerioChip® 使用可生物分解的明膠基質，可以手動將其置入牙周袋中。

凝膠劑型仍是主要的產品劑型之一。 Ligosan® 採用緩釋凝膠形式的多西環素，為臨床醫生提供了一種替代針頭式和微球式療法的選擇。

市場成熟度決定著臨床趨勢。由於許多關鍵產品已應用數十年，其成長越來越受到臨床醫生偏好、患者經濟負擔和多種治療方案競爭的驅動，而非新技術的應用。

牙周雷射治療在某些市場造成了壓力。隨著雷射牙周治療的普及，轉向技術型治療模式的診所中，局部抗菌療法的佔有率可能會下降。

地區

本報告涵蓋全球調查區域，包括北美、歐洲、亞太地區、拉丁美洲以及中東和非洲。

這份報告的意義

全球局部抗菌牙周治療市場規模有多大？預計到2032年會發生怎樣的變化？

預測期內市場預計略有收縮的原因是什麼？

銷售量、平均售價和市場規模如何隨時間變化？

病人對非手術牙周治療的偏好如何支持繼續使用局部抗菌療法？

保險償付限制如何影響牙周治療決策？

局部抗菌產品如何與齦下刮治和牙根整平術結合使用？

市場飽和度如何影響 ARESTIN（R）等旗艦產品的銷售成長？

哪些競爭對手在市場中處於領先地位？ OraPharma、PerioChip® 和 Ligosan 在市場上又處於什麼位置？

iData Research 的《全球局部抗菌牙周治療市場報告》透過詳盡的市場規模、平均售價（ASP）趨勢、預測和競爭格局分析，解答了這些問題。本報告將協助評估市場需求、對標主要競爭對手、分析治療方法的採用模式，並為局部抗菌牙周治療的未來發展制定前瞻性規劃。

目錄

調查方法

• 步驟1：專案啟動與團隊組建
• 步驟2：準備資料系統並進行二次調查。
• 步驟3：設計和準備訪談和調查問卷。
• 步驟4：進行初步調查
• 步驟5：調查與分析：建立基準估計值
• 步驟6：市場預測與分析
• 步驟7：辨識策略機會
• 步驟8：最終審核和市場推廣
• 步驟9：客戶回饋與市場監測

全球關稅的影響

局部抗菌牙周治療市場

• 執行摘要
  • 全球局部抗菌牙周治療市場概覽
  • 競爭分析
  • 目標區域
• 介紹
• 市場分析與預測
• 促進因素和抑制因素
• 競爭性市場佔有率分析

簡稱

Global Local Antimicrobial Periodontal Treatment Market Report to 2032

The global local antimicrobial periodontal treatment market was valued at over $240 million in 2025. It is expected to decrease at a compound annual growth rate (CAGR) of -0.7%, reaching just over $230 million by 2032.

This comprehensive report covers the global market for local antimicrobial periodontal treatment. The market is analyzed as a whole and is not further segmented.

The analysis includes unit sales, average selling prices (ASPs), market size, growth trends, market drivers and limiters, market forecasts through 2032, and historical data back to 2022. It also includes recent mergers and acquisitions, company profiles, product portfolios and leading competitors.

Demand is supported by patient preference for non-surgical periodontal care and the use of local antimicrobial therapies alongside scaling and root planing. However, market growth is limited by saturation, reimbursement issues and rising interest in alternative periodontal treatment methods.

Market Overview

The global local antimicrobial periodontal treatment market includes products used as adjunctive therapies for periodontal disease management. These treatments are typically applied directly into periodontal pockets to help control bacterial activity and support clinical outcomes after scaling and root planing.

The market is analyzed as a single segment because it is focused on local antimicrobial treatment rather than a broad portfolio of procedure types or device categories. Products in this category are used primarily in patients with periodontal pockets where localized treatment may help manage disease progression.

Local antimicrobial periodontal treatments provide a lower-cost and less invasive option compared with surgical periodontal procedures. This makes them relevant for patients with mild to moderate periodontal disease, especially when cost, insurance coverage or treatment preference limits surgical intervention.

Despite their clinical role, the market is expected to decline modestly over the forecast period. Demand is pressured by mature product adoption, limited reimbursement, and growing use of other periodontal treatment approaches, including laser therapy in some markets.

Market Drivers

Preference for non-surgical periodontal treatment remains the key driver of the local antimicrobial periodontal treatment market. Many patients prefer options that avoid surgery, reduce discomfort and require less recovery time. Local antimicrobial treatments can be used in routine periodontal care, often alongside scaling and root planing.

These therapies provide a practical option for patients with mild to moderate periodontal disease. By delivering antimicrobial agents directly into periodontal pockets, they can support localized disease management without requiring a more invasive procedure. This makes them useful in cases where surgery is not preferred, not required or not financially accessible.

Reimbursement limitations can also support continued use of lower-cost periodontal therapies. In many markets, dental insurance coverage for advanced periodontal procedures remains limited. This can discourage patients from pursuing higher-cost surgical interventions and maintain demand for local antimicrobial treatments as a cost-conscious alternative in periodontal disease management.

Market Limiters

Lack of reimbursement remains a major limiter in periodontal and dental treatment markets. When patients face high out-of-pocket costs, they may delay or avoid advanced periodontal care. This can affect the broader periodontal treatment pathway and limit the willingness of patients to pursue more comprehensive care.

At the same time, the local antimicrobial market itself faces pressure from maturity and saturation. Leading products have been available for many years, and the category has limited room for major expansion. In mature markets, demand is more likely to be influenced by replacement use, clinical habits and treatment protocols than by new patient adoption.

Alternative periodontal therapies also create pressure. In North America, the local antimicrobial market has been affected by the increasing popularity of periodontal laser therapy. While local antimicrobials remain relevant, competition from other treatment methods can reduce procedure share and contribute to the expected market decline over the forecast period.

Market Coverage and Data Scope

• Quantitative coverage: Market size, market shares, market forecasts, market growth rates, units sold and average selling prices.
• Qualitative coverage: Market drivers and limiters, market size and growth trends, recent mergers and acquisitions, company profiles, product portfolios and leading competitors.
• Time frame: Base year 2025, forecasts to 2032, and historical data back to 2022.
• Data types included: Unit sales, average selling prices, market size and growth trends, market drivers and limiters, market forecasts through 2032, historical data, recent mergers and acquisitions, company profiles and product portfolios.
• Method note: Market revenue is modeled using unit sales and average selling prices. Since the local antimicrobial periodontal treatment market is analyzed as a whole, the report focuses on total market performance, competitive positioning, pricing trends and treatment adoption patterns.

The report is designed to help readers evaluate how non-surgical treatment preference, reimbursement limitations, market saturation and alternative periodontal therapies are shaping the global local antimicrobial periodontal treatment market.

Markets Covered and Segmentation

Local Antimicrobial Periodontal Treatment Market

The local antimicrobial periodontal treatment market is analyzed as a whole and is not further segmented.

This market includes local antimicrobial therapies used as adjunctive treatments in periodontal care, most commonly in combination with scaling and root planing.

Each market metric is analyzed through relevant quantitative measures, including market size, market shares, market forecasts, market growth rates, units sold and average selling prices.

Competitive Analysis

OraPharma's ARESTIN(R) currently controls the majority share of the global local antimicrobial market for periodontal therapy. ARESTIN(R) is used as a local antimicrobial adjunct to scaling and root planing and contains 1 mg of minocycline hydrochloride microspheres designed to reach deep periodontal pockets.

ARESTIN(R) was originally launched in 1996 and received FDA approval in 2001. The product continues to maintain a dominant market share, but it has seen year-over-year revenue decreases and has fallen short of annual revenue forecasts. Its decline is not primarily due to loss of share to other local antimicrobials. Instead, it is being affected by overall market saturation and the increasing popularity of periodontal laser therapy, especially in North America.

PerioChip(R) emerged as the second-leading competitor globally and holds the leading position in Europe. The product is sold worldwide through distributors and is marketed by Dexcel Pharma through subsidiaries and partners across Germany, the U.K., Benelux, Austria and other countries. PerioChip(R) is a small biodegradable gelatin matrix containing 2.5 mg of chlorhexidine digluconate.

Ligosan ranked third globally in 2025 and achieved the second-largest share in Europe. Distributed primarily by Kulzer, Ligosan(R) Slow Release is a doxycycline-based gel released into periodontal pockets.

Technology and Practice Trends

Local drug delivery remains the core treatment model in this market. Products are designed to place antimicrobial agents directly into periodontal pockets, supporting localized treatment while limiting the need for more invasive intervention.

Adjunctive use with scaling and root planing remains the main clinical workflow. These treatments are not generally positioned as standalone solutions but as part of periodontal disease management.

Biodegradable delivery formats remain important because they can simplify treatment and reduce the need for removal. PerioChip(R), for example, uses a biodegradable gelatin matrix that can be placed manually into the periodontal pocket.

Gel-based delivery remains another product format. Ligosan(R) uses doxycycline in a slow-release gel form, giving clinicians an alternative to chip-based or microsphere-based treatment.

Market maturity is shaping practice trends. Many leading products have been used for decades, so growth depends less on new technology adoption and more on clinical preference, patient affordability and competitive treatment options.

Periodontal laser therapy is creating pressure in some markets. As laser-based periodontal treatments gain popularity, local antimicrobial therapies may lose share in practices that shift toward technology-based treatment models.

Geography

This report provides global coverage across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.

Why This Report

How large is the global local antimicrobial periodontal treatment market, and how is it expected to change through 2032?

Why is the market expected to decline modestly over the forecast period?

How are unit sales, average selling prices and market values changing over time?

How does patient preference for non-surgical periodontal treatment support continued use of local antimicrobial therapies?

How do reimbursement limitations influence periodontal treatment decisions?

How are local antimicrobial products used alongside scaling and root planing?

Why is market saturation affecting revenue growth for leading products such as ARESTIN(R)?

Which competitors lead the market, and how are OraPharma, PerioChip(R) and Ligosan positioned?

The Global Local Antimicrobial Periodontal Treatment Market Report from iData Research answers these questions with detailed market sizing, ASP trends, forecasts and competitive share insights. Use it to evaluate demand, benchmark leading competitors, assess treatment adoption patterns and plan around the future of local antimicrobial periodontal therapy.

TABLE OF CONTENT

Research Methodology

• Step 1: Project Initiation & Team Selection
• Step 2: Prepare Data Systems And Perform Secondary Research
• Step 3: Preparation For Interviews & Questionnaire Design
• Step 4: Performing Primary Research
• Step 5: Research Analysis: Establishing Baseline Estimates
• Step 6: Market Forecast And Analysis
• Step 7: Identify Strategic Opportunities
• Step 8: Final Review And Market Release
• Step 9: Customer Feedback And Market Monitoring

Impact Of Global Tariffs

Local Antimicrobial Periodontal Treatment Market

• 6.1 Executive Summary
  • 6.1.1 Global Local Antimicrobial Periodontal Treatment Market Overview
  • 6.1.2 Competitive Analysis
  • 6.1.3 Regions Included
• 6.2 Introduction
• 6.3 Market Analysis And Forecast
• 6.4 Drivers And Limiters
  • 6.4.1 Market Drivers
  • 6.4.2 Market Limiters
• 6.5 Competitive Market Share Analysis

Abbreviations

LIST OF CHARTS

• Chart 6-1: Local Antimicrobial Periodontal Treatment Market, Global, 2025 & 2032
• Chart 6-2: Local Antimicrobial Periodontal Treatment Procedures, Global, 2025
• Chart 6-3: Local Antimicrobial Periodontal Treatment Market, Global, 2022 - 2032
• Chart 6-4: Leading Competitors, Local Antimicrobial Periodontal Treatment Market, Global, 2025

LIST OF FIGURES

• Figure 6-1: Local Antimicrobial Periodontal Treatment Regions Covered, Global (1 of 2)
• Figure 6-2: Local Antimicrobial Periodontal Treatment Regions Covered, Global (2 of 2)
• Figure 6-3: Local Antimicrobial Periodontal Treatment Market, Global, 2022 - 2032
• Figure 6-4: Units Sold by Region, Local Antimicrobial Periodontal Treatment Market, Global, 2022 - 2032
• Figure 6-5: Average Selling Price by Region, Local Antimicrobial Periodontal Treatment Market, Global, 2022 - 2032 (US$)
• Figure 6-6: Market Value by Region, Local Antimicrobial Periodontal Treatment Market, Global, 2022 - 2032 (US$M)
• Figure 6-7: Leading Competitors, Local Antimicrobial Periodontal Treatment Market, Global, 2025